The diagnosis and therapy of tuberculosis during the past 100 years

American Journal of Respiratory and Critical Care Medicine

Volumn 171, Issue 7, 2005, Pages 699-706

  Mitchison, Denis A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMINOSALICYLIC ACID; ETHAMBUTOL; ISONIAZID; NEW DRUG; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STEROID; STREPTOMYCIN; THIOACETAZONE; UNCLASSIFIED DRUG;

BACTERICIDAL ACTIVITY; BACTERIOLOGY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; DRUG RESISTANCE; FLUOROSCOPY; HISTORY; HOME CARE; HUMAN; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; REVIEW; THORAX RADIOGRAPHY; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HISTORY, 20TH CENTURY; HUMANS; TUBERCULOSIS;

EID: 16344373224     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200411-1603OE     Document Type: Review

References (61)

1. Wei CJ, Tiu CM, Chen JD, Chou YH, Chang CY, Yu C. Computed tomography features of acute pulmonary tuberculosis. Am J Emerg Med 2004;22:171-174.
2. Seiler HE, Welstead AG, Williamson J. Report on Edinburgh X-ray campaign, 1958. Tubercle 1958;39:339-359.
3. International Union Against Tuberculosis. Technical guide for collection, storage and transport of sputum specimens and for examinations for tuberculosis by direct microscopy, 2nd ed. Paris: IUAT;1977.
4. Bennedsen J, Larsen SO. Examination for tubercle bacilli by fluorescence microscopy. Scand J Respir Dis 1966;47:114-120.
5. Sula L, Sundaresan, TK. WHO co-operative studies of a simple culture technique for the isolation of mycobacteria: comparison of the efficacy of lyophilized liquid medium with that of Loewenstein-Jensen (L-J) medium. Bull World Health Organ 1963;29:607-625.
6. Mitchison DA, Allen BW, Carrol L, Dickinson JM, Aber VR. A selective oleic acid albumin agar medium for tubercle bacilli. J Med Microbiol 1971;5:165-175.
7. Middlebrook G, Reggiardo Z, Tigertt WD. Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media. Am Rev Respir Dis 1977;115:1066-1069.
8. Marks J. Ending the routine guinea-pig test. Tubercle 1972;53:31-34.
9. Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, Conlon CP, Pasvol G, Hill AV. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 2001;163:824-828.
10. Hart PD. Chemotherapy of tuberculosis - research during the past 100 years. BMJ 1946; 2: 805-810 and 849-855.
11. Gaensler EA. The surgery for pulmonary tuberculosis. Am Rev Respir Dis 1982;125:73-84.
12. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc Soc Exp Biol Med NY 1944;55:66-69.
13. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ 1948;2:769-782.
14. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3:S231-S279.
15. Medical Research Council. Streptomycin treatment of tuberculous meningitis. Lancet 1948;1:582-596.
16. Medical Research Council. The prevention of streptomycin resistance by combined chemotherapy. BMJ 1952;1:1157-1162.
17. Fox W, Wiener A, Mitchison DA, Selkon JB, Sutherland I. The prevalence of drug-resistant tubercle bacilli in untreated patients with pulmonary tuberculosis: a national survey, 1955-56. Tubercle 1957;38:71-84.
18. International Union Against Tuberculosis. An international investigation of the efficacy of chemotherapy in previously untreated patients with pulmonary tuberculosis. Bull Int Union Tuberc 1964;34:80-191.
19. Tuberculosis Chemotherapy Centre Madras. A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India. Bull World Health Organ 1960;23:535-585.
20. Oestreicher R, Dressler SH, Russell WF, Grow JB, Middlebrook G. Observations on the pathogenicity of isoniazid-resistant mutants of tubercle bacilli for tuberculous patients. Am Rev Tuberc 1955;71:390-405.
21. Ramakrishnan CV, Bhatia AL, Devadatta S, Fox W, Narayana ASL, Selkon JB, Velu S. The course of pulmonary tuberculosis in patients excreting organisms which have acquired resistance to isoniazid: response to continued treatment for a second year with isoniazid alone or with isoniazid plus PAS. Bull World Health Organ 1962;26:1-18.
22. Mitchison DA. Treatment of tuberculosis. J R Coll Physicians Lond 1980;14:91-99.
23. Canetti G, Grumbach F. Diffusion de la streptomycine dans les lésions caséeuses des tuberculeux pulmonaire. Ann Inst Pasteur (Paris) 1953; 85:380-383.
24. Bartmann K, Freise G. Mikrobiologisch bestimmte Isoniazid-Konzentrationen im Gewebe von Tier und Mensch. Beitr Klin Tuberk Spezif Tuberkuloseforsch 1963;127:546-560.
25. Canetti G, Parrot R, Porven G, Le Lirzin M. Les faux de rifampicine dans le poumon et dans les lésions tuberculeuses de l'homme. Acta Tuberc Pneumol Belg 1969;60:315-322.
26. Tuberculosis Chemotherapy Centre Madras. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull World Health Organ 1959;21:51-144.
27. Fox W. The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis. Tubercle 1958;39:269-274.
28. Mitchison DA, Dickinson JM. Laboratory aspects of intermittent drug therapy. Postgrad Med J 1971;47:737-741.
29. Tuberculosis Chemotherapy Centre Madras. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull World Health Organ 1970;43:143-206.
30. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 1976;19:610-625.
31. Tuberculosis Research Centre Madras. Ethambutol plus isoniazid for the treatment of pulmonary tuberculosis - a controlled trial of four regimens. Tubercle 1981;61:13-29.
32. Singapore Tuberculosis Service/British Medical Research Council. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore: the results up to 30 months. Am Rev Respir Dis 1977;116:807-820.
33. Aquinas M, Allan WGL, Horsfall PAL, Jenkins PK, Wong HY, Girling D, Tall R, Fox W. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. BMJ 1972;1:765-771.
34. Mitchison DA, Selkon JB. The bactericidal activities of antituberculous drugs. Am Rev Respir Dis 1956;74S:109-116.
35. Wayne LG, Hayes LG. An in vitro model for sequential study of shift-down of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996;64:2062-2069.
36. McCune RM Jr, Tompsett R, McDermott W. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique: the conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956;104:763-803.
37. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003;7:6-21.
38. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Tubercle 1978;59:287-297.
39. Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981;123:367-371.
40. East African/British Medical Research Council. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972;1:1079-1085.
41. Mitchison DA. Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. J Appl Bacteriol 1996;81:72S-80S.
42. Jindani A, Doré CJ, Mitchison DA. The bactericidal and sterilising activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003;167:1348-1354.
43. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986;133:423-430.
44. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985;66:219-225.
45. Tuberculosis Research Centre. Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle 1983;64:73-91.
46. Batten JC, McCune RM Jr. The influence of corticotrophin and cortisone with antituberculous drugs on populations of Mycobacterium tuberculosis in tissues of mice. Br J Exp Pathol 1957;38:424-437.
47. Nunn P, Kibuga D, Gathua S, Brindle R, Imalingat A, Wasunna K, Lucas S, Gilks C, Omwega M, Were J. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991;337:627-630.
48. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for the treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004;364:1244-1251.
49. Bobrowitz ID. Ethambutol in tuberculous meningitis. Chest 1972;61:629-632.
50. Thwaites GE, Lan NTN, Dung NH, Quy HT, Oanh DTT, Thoa NTC, Hien NQ, Thuc NT, Hai NN, Bang ND, et al. The effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis (In press)
51. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000;4:796-806.
52. Davies PDO, Yew WW. Recent developments in the treatment of tuberculosis. Expert Opin Investig Drugs 2003;12:1297-1312.
53. Stover CK, Warrener P, Van Devanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000;405:962-966.
54. Andries K, Verhasselt P, Gillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:214-215.
55. Sirgel FA, Botha FJH, Parkin DP, Van de Wal BW, Donald PR, Clark PK, Mitchison DA. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother 1993;32:867-875.
56. Donald PR, Sirgel FA, Botha FJ, Seifart HI, Parkin DP, Vandenplas ML, Van de Wal BW, Maritz JS, Mitchison DA. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997;156:895-900.
57. Donald PR, Sirgel FA, Venter A, Smit E, Parkin DP, Van de Wal BW, Doré CJ, Mitchison DA. The early bactericidal activity of streptomycin. Int J Tuberc Lung Dis 2002;6:693-698.
58. Herbert D, Paramasivan CN, Venkatesan P, Kubendiran G, Prabhakar R, Mitchison DA. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40: 2296-2299.
59. Hu Y, Coates ARM, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:653-657.
60. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-426.
61. Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001; 1: 2. Available from http://www.biomedcentral. com/1471-2466/1/2. Accessed on March 1, 2005.